Alto Neuroscience Q3 net loss widens 77% to $25.12 million
ANRO•Alto Neuroscience’s third-quarter 2026 net loss widened 77% year over year to $25.12 million. It had $319.84 million in cash, cash equivalents and restricted cash at September 30, which it expects to fund planned operations through 2030.
1. Quarterly results and outlook
Research and development expenses rose 73% to $18.16 million, primarily driven by costs for the ALTO-207 PACE program. PACE-1 topline data remain expected in the second half of 2027; ALTO-207 Phase 3 adjunctive and monotherapy trials are planned for early and the second half of 2027, respectively, pending FDA alignment.
